Yüklüyor......
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of PARP inhibitors is based on the DNA repair vulnerability of many ovarian cancer cells, and multiple mechanisms of action o...
Kaydedildi:
| Yayımlandı: | Ther Adv Med Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5405993/ https://ncbi.nlm.nih.gov/pubmed/28491146 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016687254 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|